Positive Outlook for Mereo Biopharma Group Plc Driven by Strong Clinical Progress and Strategic Initiatives
Analyst Gil Blum from Needham maintains a Buy rating on Mereo Biopharma Group Plc with a price target of $5.00, citing strong clinical progress in Phase III studies and strategic initiatives. The studies are expected to yield positive results by the end of 2025, and the company is seeking a partner for its drug alvelestat. Mereo has $48.7 million in cash, supporting operations until 2027. Blum has a 39.76% success rate on stock recommendations.
Gil Blum, an analyst from Needham, maintained the Buy rating on Mereo Biopharma Group Plc. The associated price target remains the same with $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Gil Blum’s rating is based on several key factors that suggest a positive outlook for Mereo Biopharma Group Plc. The company’s ongoing Phase III Orbit and Cosmic studies are progressing as planned, with final results expected by the end of 2025. These studies are crucial as they involve patients who have been on therapy for at least 18 months, and the analysis is significantly powered to detect positive outcomes. The relationship between increased bone mineral density and reduced fractures with the use of anti-sclerostin further supports a favorable study result.
Additionally, Mereo Biopharma’s strategic initiatives contribute to the Buy rating. The company is actively seeking a partner for its drug alvelestat, which could enhance its market position. Furthermore, Mereo has retained European rights for vantictumab, a promising treatment for autosomal dominant osteopetrosis type 2, being developed with partner āshibio. Financially, Mereo is in a strong position, ending the third quarter of 2025 with $48.7 million in cash, which is expected to support operations until 2027.
Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Rocket Pharmaceuticals, and Taysha Gene Therapies. According to TipRanks, Blum has an average return of 4.7% and a 39.76% success rate on recommended stocks.
